Last checked at 7 Jun 2012 15:00
FOR IMMEDIATE RELEASE |
|
OXFORD BIOMEDICA PLC
ANNUAL GENERAL MEETING
Oxford, UK - 7 June 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:
·; Resolution 7: to empower the Directors to allot equity securities, pursuant to section 551 of the Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £3,149,585 with a further aggregate nominal amount of £3,149,585 authorised in connection with a rights issue, or where applicable, other proportionate offer;
·; Resolution 8: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;
·; Resolution 9: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days' notice.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolutions passed at the 2012 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (05 June 2012) there were 944,875,557 1p ordinary shares in issue, each carrying one vote per share.
Resolution |
Votes For | Votes at Chairman's Discretion | Votes at other proxy Discretion |
Votes Against |
Votes Withheld |
Total votes cast | Result |
Ordinary resolutions | |||||||
1 | 334,190,163 | 765,212 | 447,598 | 878,280 | 802,841 | 337,084,094 | Passed |
2 | 291,370,322 | 757,259 | 447,598 | 35,830,273 | 8,678,642 | 337,084,094 | Passed |
3 | 331,941,913 | 756,295 | 447,598 | 2,983,405 | 954,883 | 337,084,094 | Passed |
4 | 334,468,411 | 756,295 | 447,598 | 446,405 | 965,385 | 337,084,094 | Passed |
5 | 333,401,900 | 756,295 | 447,598 | 478,823 | 1,999,478 | 337,084,094 | Passed |
6 | 335,032,894 | 627,980 | 447,598 | 143,561 | 832,061 | 337,084,094 | Passed |
7 | 330,398,126 | 659,364 | 447,598 | 2,869,269 | 2,709,737 | 337,084,094 | Passed |
Special resolutions | |||||||
8 | 334,634,982 | 652,946 | 447,598 | 362,936 | 985,632 | 337,084,094 | Passed |
9 | 329,424,402 | 636,549 | 447,598 | 5,769,015 | 806,530 | 337,084,094 | Passed |
With regard to Resolution 7, this was taken on a poll called by the Chairman of the Company at the meeting and the results were as follows:
Votes For |
Votes Against |
Votes Withheld |
Total votes cast | Result |
333,155,858 | 5,793,459 | 2,787,570 | 338,949,317 | Passed |
The number of votes validly cast in relation to Resolution 7 was 338,949,317 which constitutes 35.87% of the of the issued share capital of the Company.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications | Tel: +44 (0)1865 783 000 |
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications |
Tel: +44 (0)20 7920 2360
|
Notes to editors
1. Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk.